Medical Pharmacology: Chapter: Chapter 14 — General Anesthesia Pharmacology -- Module: Module 2 — Pharmacology of Individual Inhalational Agents

Chapter: Chapter 14 — General Anesthesia Pharmacology — Module: Module 2 — Pharmacology of Individual Inhalational Agents
Tier: Tier 3 — Clinical Vignette (11 questions)

1. An 8-year-old boy with moderate persistent asthma is brought to the operating room for tonsillectomy and adenoidectomy. IV access has not been established. Thirty seconds into mask induction with the selected volatile agent, he develops audible expiratory wheeze, increased airway resistance on the breathing circuit, and oxygen saturation begins falling from 99% to 94%. Which of the following correctly identifies the agent most likely to have been chosen for induction in this patient, explains why it was the appropriate selection, and describes the correct immediate pharmacological response to the developing bronchospasm?

A) The agent most likely chosen was desflurane, selected for its rapid onset from a low blood:gas partition coefficient of 0.42; the bronchospasm represents an expected airway irritant response that resolves spontaneously as anesthetic depth increases, and the correct response is to increase the desflurane concentration to deepen anesthesia and wait for smooth muscle relaxation.
B) The agent most likely chosen was isoflurane, selected for its intermediate blood:gas partition coefficient of 1.4 and bronchodilatory properties; the bronchospasm in this scenario represents a paradoxical response specific to isoflurane in pediatric patients with atopy, and the correct response is to immediately discontinue isoflurane and switch to IV ketamine.
C) The agent most likely chosen was sevoflurane, the preferred volatile agent for pediatric inhalational induction given its non-pungent odor and bronchodilatory properties; the developing bronchospasm most likely reflects inadequate anesthetic depth rather than a direct irritant effect of sevoflurane, and the correct response is to deepen anesthesia by increasing the sevoflurane concentration, which will provide both greater bronchodilation and deeper CNS suppression of airway reflexes.
D) The agent most likely chosen was halothane, selected because it is the most potent bronchodilator among volatile agents and the preferred induction agent for asthmatic children in all settings; the developing bronchospasm represents refractory status asthmaticus requiring immediate IV aminophylline and discontinuation of the inhalational anesthetic.
E) The agent most likely chosen was nitrous oxide, selected for its analgesic properties and lack of airway irritation; the bronchospasm represents an anaphylactic reaction to the nitrous oxide molecule itself, and the correct response is immediate administration of IV epinephrine and discontinuation of all inhalational agents.

ANSWER: C

Rationale:

Sevoflurane is the agent of choice for pediatric inhalational induction in high-resource settings, combining a non-pungent odor with rapid onset (blood:gas partition coefficient 0.65) and clinically significant bronchodilation. In a child with asthma undergoing mask induction without IV access, sevoflurane is the pharmacologically appropriate selection. The bronchospasm developing 30 seconds into induction most likely reflects inadequate anesthetic depth rather than a direct irritant effect of sevoflurane itself — at light planes of anesthesia, airway reflexes remain active and any manipulation or secretions may trigger bronchospasm in a reactive airway. The pharmacologically correct response is to increase the sevoflurane concentration: this deepens anesthesia, suppresses airway reflexes through greater CNS depression, and delivers more sevoflurane to the bronchial smooth muscle where its relaxant effect is dose-dependent. As anesthetic depth increases, both bronchospasm triggers and smooth muscle tone diminish. If IV access can be rapidly established during this period, adjunctive bronchodilators (salbutamol via nebulizer or IV magnesium) may be added, but deepening sevoflurane is the immediate first-line pharmacological response available without IV access. Option A: Desflurane is absolutely contraindicated for inhalational induction at any age because it is a potent airway irritant that provokes coughing, breath-holding, and laryngospasm at induction concentrations — the opposite of what is needed in an asthmatic child. It would not be chosen for this scenario, and increasing it in the face of bronchospasm would worsen, not resolve, airway reactivity, making this option incorrect. Option B: Isoflurane has a pungent odor that causes airway irritation and is not suitable for mask induction, particularly in an asthmatic child. There is no recognized paradoxical bronchoconstrictor response to isoflurane in pediatric atopic patients; isoflurane is a bronchodilator. It would not be the chosen agent for inhalational induction in this scenario, making this option incorrect. Option C: Correct. Sevoflurane is the appropriate agent for pediatric inhalational induction in an asthmatic child; early bronchospasm during induction most likely reflects light anesthetic depth, and increasing the sevoflurane concentration deepens anesthesia and provides greater bronchodilation. Option D: While halothane is indeed a potent bronchodilator and was historically used for asthmatic children in resource-limited settings, it is not the preferred agent in high-resource settings where sevoflurane is available, due to halothane's cardiovascular disadvantages. Furthermore, developing bronchospasm during volatile anesthetic induction does not indicate refractory status asthmaticus requiring aminophylline; deepening volatile anesthesia is the appropriate first response, making this option incorrect. Option E: Nitrous oxide cannot produce surgical anesthesia as a sole agent (MAC >100%) and is not used as the sole inhalational induction agent. Nitrous oxide does not cause anaphylaxis and does not trigger bronchospasm through an IgE-mediated mechanism. This scenario does not represent anaphylaxis, making this option incorrect.

2. A 71-year-old woman with a history of retinal detachment repair 5 weeks ago — during which a sulfur hexafluoride (SF₆) intraocular gas bubble was placed — presents to the emergency department after a mechanical fall resulting in a displaced right femoral neck fracture. She requires urgent open reduction and internal fixation (ORIF). Her ophthalmologist confirms the SF₆ gas bubble is still partially present on same-day slit-lamp examination. The anesthesiologist must select a safe anesthetic plan. Which of the following correctly identifies the contraindicated agent, the mechanism of that contraindication, and an appropriate alternative?

A) Nitrous oxide is absolutely contraindicated because it diffuses into the SF₆ gas bubble far faster than SF₆ diffuses out, causing progressive bubble expansion, acute intraocular pressure elevation, and potential central retinal artery occlusion with permanent visual loss; a safe anesthetic plan uses total intravenous anesthesia with propofol and an opioid, or volatile maintenance with sevoflurane or isoflurane without nitrous oxide.
B) Sevoflurane is contraindicated because its degradation by intraocular lipid membranes generates compound A directly within the vitreous cavity, causing retinal toxicity that is potentiated by the presence of SF₆; the anesthetic plan should use desflurane, which does not undergo intraocular degradation due to its near-zero metabolic rate.
C) All volatile halogenated agents are contraindicated in patients with intraocular gas because they dissolve preferentially into the SF₆ bubble at body temperature, expanding it by displacement of the less lipid-soluble gas molecules; a safe anesthetic plan uses total intravenous anesthesia exclusively with no inhalational component.
D) Nitrous oxide is contraindicated because its sympathomimetic cardiovascular effect raises intraocular pressure indirectly through increased aqueous humor production; the bubble itself is not affected by nitrous oxide, but the elevated intraocular pressure from sympathetic stimulation in combination with the existing bubble creates a compressive risk to the central retinal artery.
E) Halothane is the only contraindicated agent because its high lipid solubility (oil:gas coefficient approximately 224) allows it to dissolve directly into the SF₆ bubble and form a halothane-SF₆ azeotrope that dramatically increases bubble volume; modern volatile agents including sevoflurane, desflurane, and isoflurane do not form this azeotrope and may be used with nitrous oxide safely.

ANSWER: A

Rationale:

The presence of an intraocular gas bubble — in this case SF₆ — is an absolute contraindication to nitrous oxide administration. The mechanism is purely physical: nitrous oxide diffuses into gas-filled body spaces approximately 34 times faster than nitrogen diffuses out. When nitrous oxide is administered in the presence of a retained SF₆ bubble, it rapidly enters the bubble far faster than SF₆ can exit, causing progressive volume expansion. The resulting increase in intraocular pressure can rise to levels sufficient to compress and occlude the central retinal artery, causing ischemic infarction of the retina and irreversible permanent visual loss. This contraindication persists until the gas bubble has fully reabsorbed — for SF₆ this takes approximately 2 to 3 months, and the ophthalmologist's confirmation that the bubble is still present 5 weeks postoperatively makes this an active, operative contraindication. A safe anesthetic plan for this urgent hip ORIF avoids nitrous oxide entirely and uses either total intravenous anesthesia (propofol infusion with an opioid) or volatile maintenance with sevoflurane, isoflurane, or desflurane in oxygen-enriched air, none of which share the diffusional expansion mechanism of nitrous oxide. Option A: Correct. Nitrous oxide is absolutely contraindicated due to diffusional expansion of the SF₆ bubble, with central retinal artery occlusion as the consequence; volatile agents without nitrous oxide or TIVA are safe alternatives. Option B: Sevoflurane does not undergo intraocular degradation to compound A; compound A is formed through CO₂ absorbent interaction in the breathing circuit, not within biological tissues. Sevoflurane is safe to use in patients with intraocular gas provided nitrous oxide is avoided; desflurane is not specifically preferred over sevoflurane for this reason, making this option incorrect. Option C: Volatile halogenated agents do not dissolve preferentially into SF₆ bubbles through a lipid displacement mechanism. The intraocular contraindication is specific to nitrous oxide's diffusional properties; volatile agents such as sevoflurane, isoflurane, and desflurane may be used safely in patients with intraocular gas when nitrous oxide is avoided, making this option incorrect. Option D: Nitrous oxide's sympathomimetic cardiovascular effect does not meaningfully raise intraocular pressure through aqueous humor production at clinical concentrations. The mechanism of intraocular harm from nitrous oxide is direct bubble expansion through rapid diffusion — a physical rather than hemodynamic mechanism — making this option incorrect. Option E: There is no halothane-SF₆ azeotrope formation, and halothane's lipid solubility does not cause it to dissolve into and expand an SF₆ bubble. The contraindication is specific to nitrous oxide based on diffusional properties, not to any halogenated volatile agent. All modern volatile agents and halothane may be used in the presence of intraocular gas provided nitrous oxide is excluded, making this option incorrect.

3. A 52-year-old woman with a BMI of 48 undergoes a 4-hour laparoscopic Roux-en-Y gastric bypass. At the end of the procedure, the surgeon reports an unexpected finding requiring urgent neurological assessment — she needs to be awake and following commands as rapidly as possible to evaluate a potential peripheral nerve injury. The anesthesiologist is choosing between sevoflurane and desflurane for maintenance and is now at the point of selecting the agent that will provide the fastest emergence. Which agent should be used for the remainder of the case, and what pharmacological property accounts for the emergence advantage in this specific patient?

A) Sevoflurane should be used because its blood:gas partition coefficient of 0.65 provides rapid emergence in all patient populations; in morbidly obese patients, the difference in emergence time between sevoflurane and desflurane is clinically negligible because both agents have low blood solubility and neither accumulates significantly in lean tissue compartments.
B) Sevoflurane should be used because it undergoes greater hepatic metabolism (3 to 5% of absorbed dose) than desflurane, and this metabolism in morbidly obese patients with enlarged hepatic blood flow produces active metabolites that accelerate cognitive recovery, shortening time to command-following despite a slightly slower pharmacokinetic offset.
C) Desflurane should be used, but only if the inspired concentration is rapidly increased to above 2 MAC to saturate adipose tissue compartments before emergence; the rapid saturation strategy paradoxically accelerates emergence by preventing redistribution from fat back into blood during washout, which is the primary cause of delayed emergence in obese patients.
D) Sevoflurane should be used because its oil:gas partition coefficient of approximately 47 is lower than desflurane's approximately 19, meaning sevoflurane is less lipid-soluble and accumulates less in the large adipose compartments of a morbidly obese patient, producing faster emergence through reduced tissue reservoir.
E) Desflurane should be used for the remainder of the case: its blood:gas partition coefficient of 0.42 and extremely low tissue solubility mean that even after 4 hours in a morbidly obese patient, desflurane does not accumulate significantly in adipose tissue relative to more soluble agents, and its rapid alveolar washout produces the fastest emergence of any halogenated volatile agent — the property most critical when urgent post-operative neurological assessment is required.

ANSWER: E

Rationale:

In a morbidly obese patient requiring the fastest possible emergence after a prolonged procedure, desflurane's pharmacokinetic profile provides a clear and clinically significant advantage over sevoflurane. The key properties are its blood:gas partition coefficient of 0.42 — the lowest of any halogenated volatile agent — and its very low tissue solubility, particularly in adipose tissue. Morbidly obese patients have substantially enlarged fat compartments that act as reservoirs for lipid-soluble agents; agents with higher lipid solubility and tissue solubility accumulate in these compartments during prolonged anesthesia and continue to re-enter the circulation during emergence, prolonging the time to adequate wakefulness. Desflurane's oil:gas partition coefficient of approximately 19, combined with its extremely low blood solubility, means that even after 4 hours of administration in a BMI 48 patient, the adipose reservoir contribution to emergence delay is minimal compared to sevoflurane (oil:gas approximately 47) or isoflurane (oil:gas approximately 99). On discontinuation, desflurane washout from the alveolus is extremely rapid, and the gradient driving continued release from adipose tissue into blood is minimal given its low tissue partitioning. Multiple clinical studies of morbidly obese patients undergoing bariatric procedures have confirmed that desflurane provides significantly faster emergence and earlier time to extubation than sevoflurane or isoflurane — making it the pharmacologically optimal choice when rapid post-operative assessment is a clinical imperative. Option A: While sevoflurane does have low blood solubility and rapid emergence relative to older agents, the difference between sevoflurane and desflurane is not negligible in morbidly obese patients — it is precisely in prolonged cases in patients with large adipose compartments that the tissue solubility advantage of desflurane becomes most clinically relevant. Dismissing the difference as negligible in this population understates a well-documented pharmacokinetic distinction, making this option incorrect. Option B: Desflurane's lower hepatic metabolism relative to sevoflurane is not a disadvantage — it is a safety advantage. The claim that sevoflurane's higher metabolism generates active metabolites that accelerate cognitive recovery has no pharmacological basis; sevoflurane's metabolites (inorganic fluoride and hexafluoroisopropanol) are not CNS-active and do not facilitate awakening, making this option incorrect. Option C: Rapidly increasing desflurane to above 2 MAC to saturate adipose tissue before emergence is not a recognized clinical strategy and would be pharmacologically counterproductive: higher inspired concentrations increase the alveolar-to-tissue gradient and drive more agent into adipose and tissue compartments, increasing the reservoir rather than reducing redistribution during washout. This option describes an approach that would worsen rather than improve emergence speed, making it incorrect. Option D: This option inverts the oil:gas partition coefficients of sevoflurane and desflurane. Desflurane has the lower oil:gas coefficient of approximately 19, not sevoflurane (approximately 47); lower oil:gas means lower lipid solubility. Stating that sevoflurane has a lower oil:gas coefficient than desflurane is factually incorrect and leads to the wrong clinical conclusion, making this option incorrect. Option E: Correct. Desflurane's blood:gas coefficient of 0.42 and low tissue solubility minimize adipose accumulation during prolonged surgery in a morbidly obese patient, producing the fastest emergence and earliest neurological assessment capability of any halogenated volatile agent.

4. A 61-year-old man with a history of hypertension and stable angina is 45 minutes into a desflurane-based anesthetic for laparoscopic cholecystectomy. Vital signs have been stable at a heart rate of 72 beats/min and blood pressure of 124/78 mmHg. The anesthesiologist increases the desflurane concentration from 5% to 10% over approximately 20 seconds. Within 60 seconds the heart rate rises to 118 beats/min and blood pressure to 178/104 mmHg. The ECG shows new ST-segment depression in leads II and V5. Which of the following correctly identifies what has occurred, explains the mechanism, and describes the appropriate immediate management?

A) The hemodynamic response represents an acute hypertensive crisis from desflurane-induced direct stimulation of vascular alpha-1 adrenergic receptors; the ST depression reflects demand ischemia from elevated afterload, and the appropriate response is to administer IV phentolamine to block alpha-1 receptors while maintaining the current desflurane concentration.
B) The rapid increase in desflurane concentration has triggered a reflex sympathetic surge through stimulation of pulmonary irritant receptors, producing tachycardia, hypertension, and increased myocardial oxygen demand sufficient to precipitate demand ischemia in this patient with underlying coronary artery disease; immediate management includes reducing the desflurane concentration, administering IV esmolol or nitroglycerin to control heart rate and blood pressure, and evaluating for ongoing ischemia.
C) The hemodynamic response represents malignant hyperthermia (MH) triggered by the increase in desflurane concentration; tachycardia and hypertension are the earliest signs, and ST depression reflects myocardial involvement; immediate management requires discontinuing desflurane, administering IV dantrolene (2.5 mg/kg), and converting to total intravenous anesthesia.
D) The hemodynamic response represents a vasovagal reflex paradoxically triggered by the rapid increase in desflurane concentration through stimulation of pulmonary stretch receptors; the initial tachycardia will convert to bradycardia within 2 to 3 minutes as the Bezold-Jarisch reflex completes, and the ST depression will resolve without intervention as the reflex terminates.
E) The hemodynamic response represents awareness under anesthesia — the patient is consciously perceiving pain from the surgical stimulus and mounting a stress response; the ST depression reflects catecholamine-induced coronary spasm from the pain response, and the appropriate management is to immediately administer IV midazolam for amnesia and increase the opioid infusion rate.

ANSWER: B

Rationale:

This clinical scenario is a textbook presentation of the sympathetic surge associated with rapid desflurane concentration increases. Desflurane stimulates pulmonary irritant receptors when its inspired concentration is increased rapidly — a response mediated through afferent signals relayed via vagal pathways to the brainstem and then through efferent sympathetic outflow to the heart and vasculature. The resulting acute increase in sympathetic tone produces tachycardia and hypertension within 60 to 90 seconds of the concentration change, precisely as described. In a patient with underlying coronary artery disease and hypertension, this sympathetic surge is particularly dangerous: the combination of tachycardia (reduced diastolic filling time and increased myocardial oxygen demand) and hypertension (increased wall stress and afterload) raises the rate-pressure product to ischemic levels, directly producing the ST-segment depression. This is a pharmacologically predictable and avoidable complication that should have been prevented by increasing desflurane concentration gradually. Immediate management requires reversing the hemodynamic derangement: reducing the desflurane concentration removes the ongoing irritant stimulus, and IV esmolol (a short-acting beta-1 blocker) controls heart rate while IV nitroglycerin addresses coronary vasodilation and preload reduction. Continuous ECG monitoring for ischemia resolution is essential, and cardiology consultation should be considered if ST changes persist. Option A: Desflurane does not directly stimulate vascular alpha-1 adrenergic receptors. The sympathetic surge is a reflex response mediated through pulmonary irritant receptor stimulation, not direct vascular adrenergic agonism. Phentolamine would not address the ongoing irritant receptor stimulation or the heart rate elevation, and maintaining the current high desflurane concentration would perpetuate the sympathetic drive, making this option incorrect. Option B: Correct. Rapid desflurane concentration increase stimulated pulmonary irritant receptors, producing reflex sympathetic tachycardia and hypertension sufficient to precipitate demand ischemia in a patient with coronary artery disease; management requires reducing desflurane concentration and controlling the hemodynamic response with esmolol and nitroglycerin. Option C: Malignant hyperthermia presents with a constellation of findings including rising temperature, muscle rigidity, masseter spasm, combined metabolic and respiratory acidosis, hyperkalemia, and myoglobinuria — not isolated tachycardia and hypertension following a desflurane concentration increase. The timing (60 seconds after a concentration change) and the known pharmacological mechanism of desflurane sympathetic surge make MH an incorrect diagnosis here; administering dantrolene without the appropriate clinical picture would be incorrect management, making this option incorrect. Option D: No vasovagal or Bezold-Jarisch reflex produces the pattern described — an abrupt sympathetic surge with tachycardia and hypertension converting spontaneously to bradycardia. The Bezold-Jarisch reflex produces bradycardia and hypotension from cardiac mechanoreceptor stimulation, not this sequence. The ST depression represents real ischemia requiring active management, not a self-terminating reflex, making this option incorrect. Option E: Awareness under anesthesia is a possibility in any case but would not explain the specific temporal relationship between the desflurane concentration increase and the hemodynamic change. The ST depression here is demand ischemia from the pharmacologically predictable sympathetic surge, not catecholamine-induced coronary spasm from pain perception, and the appropriate response is desflurane reduction and hemodynamic control rather than amnesia induction with midazolam, making this option incorrect.

5. A 34-year-old woman with a 10-year history of generalized epilepsy, currently managed with levetiracetam, is scheduled for awake craniotomy with intraoperative cortical mapping for resection of a left temporal lobe lesion adjacent to the speech area. The plan involves an asleep-awake-asleep technique in which the patient is anesthetized for skull opening, awakened and cooperative for mapping, then re-anesthetized for closure. The neuroanesthesiologist is reviewing volatile agent selection for the asleep phases. Which of the following correctly identifies the volatile agent that must not be used in this patient and explains why it is specifically contraindicated?

A) Desflurane must not be used because its rapid concentration changes during the asleep-to-awake transition produce sympathetic surges that destabilize blood pressure during the critical mapping phase, and the resulting hemodynamic instability makes accurate cortical mapping impossible by altering cerebral perfusion pressure and distorting the electrocorticographic baseline.
B) Halothane must not be used because its high blood:gas partition coefficient of 2.4 makes the transition from asleep to awake during the mapping phase unpredictably prolonged; patients may remain anesthetized for 20 to 30 minutes longer than intended, making time-sensitive cortical mapping logistically untenable.
C) Isoflurane must not be used because at concentrations above 0.5 MAC it produces irreversible cortical depression that prevents recovery of speech and motor function during the awake mapping phase, even after the agent is discontinued, due to persistent GABA-A receptor conformational changes that outlast the agent's presence in the CNS.
D) Enflurane must not be used in this patient: it is the only volatile anesthetic with clinically significant epileptogenic potential, capable of producing EEG spike-and-wave activity and generalized tonic-clonic seizures at high concentrations or with hypocapnia, and it is formally contraindicated in patients with known seizure disorders — a contraindication that applies with particular force in a patient undergoing neurosurgery for epilepsy-adjacent pathology with intraoperative cortical mapping.
E) Sevoflurane must not be used because isolated reports of EEG spike activity with sevoflurane indicate it is formally contraindicated in all patients with prior seizure history, and its use in awake craniotomy for cortical mapping is specifically prohibited by international neuroanesthesia guidelines regardless of the concentration used.

ANSWER: D

Rationale:

Enflurane is the only volatile anesthetic with clinically significant and well-established epileptogenic potential. At inspired concentrations above approximately 2 MAC or in the presence of hypocapnia, enflurane produces characteristic high-amplitude spike-and-wave EEG complexes that can progress to generalized tonic-clonic seizure activity. This property is dose-dependent, unique among the volatile agents, and is directly linked to enflurane's molecular interaction with neuronal membrane excitability. The contraindication in a patient with known epilepsy is categorical: the risk of intraoperative seizures is substantially elevated in a patient with pre-existing lowered seizure threshold, and seizure activity during cortical mapping would not only be dangerous but would invalidate the neurophysiological data being collected, disrupt the awake-asleep transition, and potentially produce status epilepticus in a patient whose skull is open. Modern volatile agents — isoflurane, sevoflurane, and desflurane — are preferred for awake craniotomy and do not carry this epileptogenic contraindication, though all are used at low concentrations and discontinued during the awake mapping phase. Isoflurane at high doses produces burst suppression (a deeply depressed EEG), which is the opposite of epileptogenicity. Sevoflurane has isolated case reports of EEG activity but is not formally contraindicated in seizure disorders in the way enflurane is. Option A: While desflurane concentration changes during the asleep-to-awake transition do require careful management to avoid sympathetic surges, this is a practical management consideration rather than a contraindication based on seizure risk. Desflurane's rapid offset is actually advantageous for the awake phase transition, and hemodynamic management during this phase is routinely accomplished; desflurane is not contraindicated in seizure disorders, making this option incorrect. Option B: Halothane's high blood:gas coefficient does produce slower emergence, which is a kinetic disadvantage for awake craniotomy techniques, but prolonged emergence is a practical logistical challenge, not an absolute contraindication. More critically, halothane does not share enflurane's epileptogenic property and is not categorically contraindicated in seizure disorders, making this option incorrect. Option C: Isoflurane does not produce irreversible cortical depression through persistent GABA-A receptor conformational changes. Its CNS effects fully resolve as the agent is eliminated; the GABA-A potentiation produced by volatile agents is reversible and dissipates with the agent's disappearance from the CNS. Isoflurane at high doses produces burst suppression, which is the opposite of epileptogenicity, and it is not contraindicated in patients with seizure disorders, making this option incorrect. Option D: Correct. Enflurane is the only volatile agent formally contraindicated in patients with seizure disorders due to its unique epileptogenic potential, and this contraindication is specifically relevant in a patient with known epilepsy undergoing neurosurgery with intraoperative cortical mapping. Option E: Sevoflurane has isolated case reports of EEG spike activity and is used with caution in patients with seizure disorders, but it is not formally contraindicated in all patients with prior seizure history, and no international neuroanesthesia guideline categorically prohibits sevoflurane in awake craniotomy regardless of concentration. The absolute, categorical contraindication in seizure disorders belongs to enflurane, making this option an overstatement that is incorrect.

6. A 34-year-old non-smoking woman is scheduled for a 2.5-hour laparoscopic hysterectomy. She has a history of postoperative nausea and vomiting (PONV) after her two previous general anesthetics. Her Apfel score — a validated scoring system where each risk factor (female sex, non-smoker, history of PONV or motion sickness, planned postoperative opioid use) adds one point — is 4 out of 4. The anesthesiologist plans a volatile-based anesthetic and asks whether to include 60% nitrous oxide to reduce volatile agent requirements. Which of the following best represents the evidence-based recommendation and its pharmacological rationale?

A) Nitrous oxide at 60% should be included because its MAC-sparing effect reduces the required sevoflurane concentration by approximately 50%, and lower sevoflurane concentrations are associated with proportionally lower PONV risk; the net effect of adding nitrous oxide is a reduction in total PONV incidence compared to higher-concentration sevoflurane alone.
B) Nitrous oxide is safe to include in this patient because the PONV risk attributable to nitrous oxide applies only to procedures exceeding 4 hours; for a 2.5-hour procedure the number needed to harm is greater than 50, making the incremental PONV risk from nitrous oxide clinically negligible regardless of Apfel score.
C) Nitrous oxide should be avoided in this patient: its use increases PONV in a duration-dependent manner, and for procedures exceeding 2 hours the number needed to harm falls substantially; in a patient with an Apfel score of 4 — indicating maximum baseline PONV risk — nitrous oxide avoidance is a component of evidence-based multimodal PONV prevention alongside TIVA with propofol, multimodal antiemetic prophylaxis, and opioid minimization.
D) Nitrous oxide should be included because the PONV risk it adds is offset by its analgesic properties, which reduce intraoperative and postoperative opioid requirements; because opioids are themselves a major contributor to PONV, the net effect of nitrous oxide on postoperative nausea is neutral or beneficial through the opioid-sparing mechanism.
E) Nitrous oxide is contraindicated in laparoscopic procedures regardless of PONV risk because it diffuses into the pneumoperitoneum carbon dioxide gas and expands the abdominal working space unpredictably, creating a risk of visceral injury from trocar displacement during insufflation.

ANSWER: C

Rationale:

The evidence base for nitrous oxide and PONV is well-established and directly applicable to this clinical scenario. Nitrous oxide increases PONV incidence through mechanisms including stimulation of the chemoreceptor trigger zone via dopaminergic and opioid pathways, as well as direct gastrointestinal effects. Critically, this risk is duration-dependent: the number needed to harm (the number of patients who must receive nitrous oxide for one additional PONV case to occur compared to a nitrous oxide-free technique) falls progressively with procedure duration. For procedures under one hour the number needed to harm exceeds 100, but for procedures exceeding two hours it falls to approximately 9 — meaning roughly 1 in 9 patients receiving nitrous oxide for a procedure over 2 hours will develop PONV attributable to it who would not have otherwise. This patient's 2.5-hour procedure places her firmly in the range where nitrous oxide makes a clinically meaningful PONV contribution. Combined with her Apfel score of 4 — the maximum, indicating female sex, non-smoker status, prior PONV history, and postoperative opioid use — she is at the highest possible baseline PONV risk. Nitrous oxide avoidance is a zero-cost intervention and is supported as a component of multimodal PONV prevention in high-risk patients alongside total intravenous anesthesia with propofol (which has intrinsic antiemetic properties), dual or triple antiemetic prophylaxis (5-HT3 antagonist, dexamethasone, and scopolamine patch), and opioid minimization through regional analgesia or non-opioid adjuncts. Option A: The premise that lower sevoflurane concentrations reduce PONV proportionally is not supported by evidence — the volatile anesthetic component of PONV risk is not as steeply dose-dependent as the nitrous oxide component, and the MAC-sparing benefit of nitrous oxide does not offset its direct PONV contribution. Adding nitrous oxide in a high-risk patient increases rather than decreases net PONV risk, making this option incorrect. Option B: The PONV risk from nitrous oxide is not negligible for procedures under 4 hours. The 2-hour threshold is the clinically relevant cutoff where the number needed to harm reaches approximately 9 — a level that is clinically significant, particularly in an Apfel score 4 patient. The 4-hour threshold cited in this option is incorrect, making it incorrect. Option C: Correct. Nitrous oxide's duration-dependent PONV risk, combined with this patient's maximum Apfel score and a 2.5-hour procedure, makes nitrous oxide avoidance an evidence-based component of multimodal PONV prevention; the recommendation is supported by meta-analytic data on PONV incidence and number needed to harm. Option D: While nitrous oxide does have analgesic and opioid-sparing properties, the net effect on PONV is not neutral or beneficial in high-risk patients — the direct PONV-promoting mechanism outweighs any benefit from modest opioid reduction, particularly in a patient with Apfel score 4 and a procedure duration where the number needed to harm is approximately 9, making this option incorrect. Option E: Nitrous oxide does not diffuse into the pneumoperitoneum carbon dioxide and expand it in a clinically dangerous way during standard laparoscopic procedures. Carbon dioxide is used specifically as the insufflation gas because of its high solubility and rapid absorption, and nitrous oxide does not create uncontrolled expansion of the surgical working space. This option describes a non-existent clinical risk, making it incorrect.

7. A 48-year-old woman undergoes elective cholecystectomy under halothane anesthesia at a district hospital. She had a halothane anesthetic for appendectomy 6 weeks earlier at the same facility. Her intraoperative and immediate postoperative course are unremarkable. On postoperative day 5 she develops fever, jaundice, markedly elevated transaminases (AST 2,840 U/L, ALT 3,210 U/L), and coagulopathy with INR 4.2. There is no evidence of biliary obstruction on imaging. Which of the following correctly identifies the syndrome, its mechanism, and the specific risk factor most responsible for its severity in this patient?

A) This presentation is consistent with Type II halothane hepatitis — a rare immune-mediated fulminant hepatitis in which CYP2E1 (cytochrome P450 2E1)-mediated oxidative metabolism of halothane generates trifluoroacetyl chloride, which covalently binds to hepatic proteins forming trifluoroacetylated neoantigens; prior halothane exposure 6 weeks earlier sensitized the immune system to these neoantigens, and re-exposure triggered an accelerated and amplified immune-mediated hepatocellular destruction with approximately 50% mortality when fulminant.
B) This presentation is consistent with Type I halothane hepatotoxicity — the common, self-limited form affecting approximately 20 to 30% of halothane-exposed patients — in which direct hepatocellular injury from trifluoroacetyl chloride metabolites causes transient transaminase elevation; the severity in this patient reflects her individual CYP2E1 ultrarapid metabolizer genotype, which generates 10 to 20 times the normal quantity of toxic metabolites from a standard anesthetic dose.
C) This presentation is consistent with halothane-induced mitochondrial hepatotoxicity — a mechanism in which halothane's reductive metabolite bromide ion accumulates in hepatic mitochondria, uncoupling oxidative phosphorylation and causing ATP depletion-mediated hepatocellular necrosis; re-exposure within 6 weeks is not a risk factor because bromide ion is fully cleared within 72 hours of each exposure.
D) This presentation is consistent with sevoflurane-associated hepatitis, which occurs when patients previously sensitized to halothane-related trifluoroacetylated proteins mount a cross-reactive immune response to compound A generated by sevoflurane metabolism; the severity of hepatic dysfunction reflects cross-sensitization from the prior halothane exposure at the molecular level of the trifluoroacetyl epitope.
E) This presentation is consistent with anesthesia-induced cholestasis from halothane's potent inhibition of bile canalicular multidrug resistance protein 2 (MRP2) — the transporter responsible for bile salt excretion — producing progressive intrahepatic cholestasis with secondary hepatocellular necrosis; re-exposure at 6 weeks is not a risk factor as MRP2 inhibition is not immune-mediated and does not involve sensitization.

ANSWER: A

Rationale:

The clinical presentation — postoperative day 5 onset of fever, jaundice, markedly elevated transaminases, and coagulopathy following a second halothane anesthetic within 6 weeks — is a classic and textbook presentation of Type II halothane hepatitis. The pathophysiological sequence is well-established: halothane undergoes approximately 20% hepatic metabolism via CYP2E1, producing an oxidative metabolite, trifluoroacetyl chloride, that covalently binds to hepatic microsomal proteins through a process called trifluoroacetylation. The resulting trifluoroacetylated protein adducts are recognized by the immune system as foreign neoantigens, initiating an immune sensitization response on first exposure. On re-exposure — particularly at short intervals such as the 6-week interval in this patient — the primed immune system mounts a rapid and amplified immune-mediated hepatocellular attack against trifluoroacetylated hepatic proteins, producing fulminant hepatitis. The mortality from fulminant Type II halothane hepatitis is approximately 50%. The risk of Type II hepatitis increases dramatically with repeated exposures at short intervals (under 3 months); exposures at longer intervals carry lower but non-zero risk. The 6-week interval in this patient is precisely in the high-risk range. Type I halothane hepatotoxicity — the common mild form — is a direct toxic injury not requiring sensitization and produces a much milder transaminase elevation without fulminant course. Option A: Correct. Type II halothane hepatitis is an immune-mediated fulminant hepatitis caused by trifluoroacetylated neoantigen formation; prior exposure 6 weeks earlier is the critical risk factor that sensitized the immune system, and re-exposure triggered amplified immune-mediated hepatocellular destruction with approximately 50% mortality. Option B: This option describes Type I halothane hepatotoxicity, which is the common mild form producing transient transaminase elevation, not the fulminant presentation described. Type I does not typically produce INR of 4.2, coagulopathy, or jaundice of this severity. Additionally, CYP2E1 ultrarapid metabolizer genotype is not an established mechanism of Type I severity in the way described, making this option incorrect. Option C: Bromide ion, the reductive metabolite of halothane, is not the mechanism of either type of halothane hepatotoxicity. Trifluoroacetyl chloride from oxidative metabolism is the key intermediate. Bromide accumulation causing mitochondrial uncoupling is not a recognized mechanism of halothane hepatotoxicity, and the claim that re-exposure risk is absent because bromide is cleared within 72 hours misidentifies the mechanism entirely, making this option incorrect. Option D: The patient received halothane, not sevoflurane, for the second procedure; the hepatitis is halothane-related, not sevoflurane-related. Sevoflurane does generate trace trifluoroacetylated protein, but the clinical significance of cross-reactivity between halothane-sensitized patients and sevoflurane metabolites is a theoretical concern, not a well-established cause of fulminant hepatitis. The described presentation follows a halothane re-exposure, not a sevoflurane exposure, making this option incorrect. Option E: Halothane hepatotoxicity is not mediated through MRP2 (multidrug resistance protein 2) inhibition and intrahepatic cholestasis. The mechanism is trifluoroacetylation of hepatic proteins triggering immune-mediated hepatocellular destruction, not transporter inhibition causing cholestasis. The claim that re-exposure risk is absent because the mechanism is non-immune is factually incorrect for Type II hepatitis, making this option incorrect.

8. A 5-year-old boy is in the post-anesthesia care unit (PACU) 12 minutes after a sevoflurane-based general anesthetic for myringotomy and bilateral ear tube placement, a procedure lasting 9 minutes. He is inconsolably crying, thrashing in the bed, kicking at nursing staff, and staring blankly without making eye contact. He does not respond to his mother calling his name or reaching for him. His oxygen saturation is 99% on room air, heart rate is 128 beats/min, and there is no evidence of surgical site trauma. The PACU nurse asks whether to administer IV morphine for pain. Which of the following best identifies the diagnosis, explains how to distinguish it from pain, and guides appropriate management?

A) This presentation is consistent with opioid-induced delirium from residual fentanyl given intraoperatively; the blank stare and failure to recognize the mother indicate miosis-associated visual impairment from opioid effect, and the correct response is to administer IV naloxone 0.01 mg/kg to reverse the opioid effect and restore normal consciousness.
B) This presentation is consistent with sevoflurane emergence agitation — a self-limited dysphoric transitional state that is specifically associated with sevoflurane's rapid offset, with peak incidence in preschool children aged 2 to 6 undergoing brief ENT procedures; it is distinguished from pain by the absence of purposeful pain behaviors (the child is not guarding a wound site, there is no surgical pain source after a 9-minute myringotomy), the non-consolable and non-directed nature of the distress, and the failure to recognize familiar caregivers; morphine is not indicated and carries risks of respiratory depression, and the appropriate management is reassurance, a safe environment, parental presence, and if persistent, a small dose of IV propofol (0.5 to 1 mg/kg) or dexmedetomidine.
C) This presentation is consistent with hypoglycemia from prolonged preoperative fasting in a young child; the thrashing and blank stare represent neuroglycopenic symptoms, and the correct response is immediate IV dextrose administration with a point-of-care glucose measurement to confirm before treatment.
D) This presentation is consistent with laryngospasm-associated hypoxic encephalopathy from a periextubation event; despite the currently normal oxygen saturation, the behavior represents post-hypoxic cortical dysfunction that typically peaks 10 to 20 minutes after the hypoxic event, and the correct response is urgent CT brain imaging and neurology consultation.
E) This presentation is consistent with a paradoxical reaction to midazolam premedication; the disinhibited, aggressive behavior represents midazolam-induced cortical disinhibition that is potentiated by sevoflurane exposure and does not resolve until midazolam is pharmacologically reversed with IV flumazenil 0.01 mg/kg.

ANSWER: B

Rationale:

This presentation is a prototypical case of sevoflurane emergence agitation. The clinical profile integrates every known high-risk factor simultaneously: the child is 5 years old (within the peak incidence age of 2 to 6), the surgical procedure was a brief ENT procedure (myringotomy — among the highest-risk procedure categories for emergence agitation), and the sevoflurane-based anesthetic lasted only 9 minutes, producing the most abrupt pharmacokinetic offset and steepest dysphoric transitional state. The key clinical skill in this scenario is distinguishing emergence agitation from pain. Distinguishing features in this vignette: the child is inconsolable regardless of maternal presence (pain in young children typically responds at least partially to comforting), the distress is non-directed (no guarding, no pointing to or protecting a wound site), the procedure was a myringotomy which produces minimal postoperative pain, and the child fails to recognize his mother — a feature of the dysphoric transitional state of emergence agitation that is not typical of a simply painful child. Administering IV morphine is not appropriate: it would not address the pharmacological mechanism of emergence agitation, delays resolution, and introduces respiratory depression risk in an extubated child. The correct management is a safe, calm environment with the parent present, waiting for spontaneous resolution (typically within 15 to 30 minutes), and if the behavior is persistent or endangers the child, a small IV dose of propofol (0.5 to 1 mg/kg) to smooth the emergence, or dexmedetomidine 0.3 to 0.5 mcg/kg IV. Option A: There is no clinical indication of opioid toxicity in this scenario — no respiratory depression, no miosis mentioned, no clinical signs of opioid excess. The blank stare in emergence agitation reflects the dysphoric transitional state of cortical reintegration, not visual impairment from opioids. Naloxone administration would be inappropriate in a child with normal oxygen saturation and no signs of opioid overdose, and would not address emergence agitation, making this option incorrect. Option B: Correct. The presentation is sevoflurane emergence agitation in a high-risk patient (peak age, brief ENT procedure, abrupt sevoflurane offset); it is distinguished from pain by non-directed behavior, absence of pain source, and failure to recognize familiar caregivers; morphine is not appropriate, and management is parental presence, safe environment, and propofol or dexmedetomidine if needed. Option C: While hypoglycemia is a consideration in fasted pediatric patients, the oxygen saturation of 99%, the clinical specificity of the presentation to the post-sevoflurane period, the procedure type, and the age all point strongly to emergence agitation rather than hypoglycemia. Hypoglycemia-related behavioral changes in children are typically preceded by other signs (pallor, diaphoresis, tremulousness) and would be expected to have been identified preoperatively. A glucose check is always reasonable but immediate IV dextrose without confirmation is not the priority management here, making this option incorrect. Option D: The normal oxygen saturation of 99% on room air does not support post-hypoxic encephalopathy, and there is no clinical history of laryngospasm or hypoxic event in this case. Post-hypoxic cortical dysfunction does not characteristically present as a brief, self-limited behavior pattern in an otherwise well-oxygenated child after a 9-minute procedure; this option introduces a catastrophic diagnosis without supportive clinical evidence, making it incorrect. Option E: Midazolam paradoxical reactions are recognized but typically manifest as hyperactive, disinhibited behavior in an otherwise conscious and communicative child; they do not produce the blank stare, failure to recognize caregivers, or the emergence-specific temporal pattern described here. Flumazenil to reverse midazolam is not the appropriate response to emergence agitation, which is sevoflurane-related rather than benzodiazepine-related, making this option incorrect.

9. A 55-year-old man is scheduled for resection of a posterior fossa meningioma. The neurosurgeon prefers the sitting position to optimize surgical access and reduce venous bleeding. The anesthesiologist is planning the anesthetic and reviewing which inhalational agents may be used. The attending neuroanesthesiologist mentions that one specific inhalational agent carries a unique risk in the sitting craniotomy position that makes its use contraindicated for this case. Which of the following correctly identifies that agent, the specific mechanism of concern, and why the sitting position amplifies the risk?

A) Desflurane is contraindicated in sitting craniotomy because its sympathetic surge with rapid concentration increases produces sudden hypertension that, in the sitting position, creates a critically elevated transmural pressure in bridging veins crossing the subdural space, dramatically increasing the risk of bridging vein rupture and subdural hematoma during posterior fossa dissection.
B) Halothane is contraindicated in sitting craniotomy because its potent uterine relaxant properties cross-react with intracranial dural venous sinus smooth muscle in the posterior fossa, causing dural sinus dilation that increases venous air embolism trapping capacity when the surgical site is above the level of the heart.
C) Nitrous oxide is contraindicated or must be used with extreme caution in sitting craniotomy because air embolism — the entry of atmospheric air into an open venous sinus when the surgical site is above the level of the heart — is a specific and well-recognized risk of the sitting position; nitrous oxide diffuses into air emboli far faster than nitrogen diffuses out, expanding any venous air embolism and potentially converting a small hemodynamically insignificant air embolism into a large, obstructive, and potentially fatal embolus.
D) Sevoflurane is contraindicated in sitting craniotomy because the combination of cerebrovascular vasodilation from sevoflurane and the venous pooling that occurs in the sitting position produces a critical reduction in cerebral perfusion pressure through a synergistic mechanism that no other volatile agent shares at clinical maintenance concentrations.
E) Isoflurane is contraindicated in sitting craniotomy because its coronary vasodilatory steal mechanism, when combined with the reduced cardiac preload from venous pooling in the sitting position, produces a compound reduction in coronary perfusion pressure that precipitates myocardial ischemia in the majority of patients with any degree of coronary artery disease undergoing posterior fossa surgery.

ANSWER: C

Rationale:

Venous air embolism (VAE) is a well-recognized and potentially life-threatening complication of surgery performed in the sitting position. When the surgical site is positioned above the level of the heart, subatmospheric venous pressure at the wound site means that if a venous sinus or bridging vein is opened, atmospheric air can be entrained into the circulation rather than blood flowing out. The sitting craniotomy for posterior fossa surgery represents one of the highest-risk scenarios for this complication because the posterior fossa contains multiple large venous sinuses (transverse, sigmoid, occipital) that may be entered during dissection, and the sitting position maximizes the height differential between the surgical site and the right heart. Nitrous oxide creates a specific and compounding risk in this context: because it diffuses into gas-filled spaces approximately 34 times faster than nitrogen diffuses out, any air embolism that enters the circulation in the presence of nitrous oxide will rapidly expand as nitrous oxide diffuses in. A small venous air embolism that would otherwise pass through the pulmonary vasculature without hemodynamic consequence can be converted into a large, obstructive embolism capable of producing right heart outflow tract obstruction, cardiovascular collapse, and paradoxical arterial embolism through a patent foramen ovale. For this reason, nitrous oxide is either contraindicated or used only with extreme caution in sitting craniotomy cases, and many neuroanesthesiologists avoid it entirely for this indication. Option A: While desflurane's sympathetic surge with rapid concentration increases is a genuine clinical concern in patients with cardiovascular risk, this is not the mechanism that makes any volatile agent specifically contraindicated in sitting craniotomy. Bridging vein rupture from hypertension is not a recognized complication of desflurane-related sympathetic surges in neurosurgery, making this option incorrect. Option B: Halothane's uterine relaxant properties are specific to myometrial smooth muscle and do not cross-react with dural venous sinus tissue. There is no pharmacological mechanism by which halothane dilates venous sinuses or increases VAE trapping capacity, and this option describes a non-existent mechanism, making it incorrect. Option C: Correct. Nitrous oxide diffuses into venous air emboli far faster than nitrogen exits, expanding any air embolism and potentially converting a small hemodynamically insignificant event into a large, obstructive, fatal embolus — the specific mechanism of its contraindication or extreme caution in sitting craniotomy where venous air embolism risk is highest. Option D: While sevoflurane does cause cerebrovascular vasodilation, this is a property shared by all volatile agents and is managed with appropriate ventilation and blood pressure control in neurosurgery. There is no synergistic mechanism with sitting position venous pooling that is specific to sevoflurane and not shared by other agents, and sevoflurane is routinely used for sitting craniotomy cases, making this option incorrect. Option E: Isoflurane's coronary vasodilation and the theoretical steal mechanism are not the basis for a contraindication in sitting craniotomy, and isoflurane does not cause myocardial ischemia in the majority of patients with coronary artery disease. The reduced preload from sitting position venous pooling is a hemodynamic management challenge addressed through volume loading and vasopressors, not a reason to avoid isoflurane, making this option incorrect.

10. A 63-year-old man with end-stage renal disease (ESRD) on thrice-weekly hemodialysis is scheduled for creation of an arteriovenous fistula under general anesthesia. The anesthesiologist is considering sevoflurane for maintenance and reviews the renal safety concerns associated with this agent. Which of the following correctly identifies the specific metabolite concerns for sevoflurane in this patient, assesses their clinical relevance, and determines whether sevoflurane is appropriate?

A) Sevoflurane is contraindicated in patients with ESRD because inorganic fluoride ions generated by CYP2E1 (cytochrome P450 2E1) metabolism accumulate to nephrotoxic levels in anuric patients who cannot excrete fluoride renally; the resulting fluoride retention produces a progressive fluoride intoxication syndrome causing cardiac arrhythmias, bone demineralization, and CNS toxicity that is not corrected by hemodialysis because fluoride is not effectively dialyzed.
B) Sevoflurane is contraindicated in patients on hemodialysis because compound A — generated by CO₂ absorbent degradation of sevoflurane — accumulates in the circulation of anuric patients who cannot excrete it renally, reaching nephrotoxic concentrations within 30 minutes of sevoflurane administration and causing irreversible tubular necrosis that prevents renal recovery even after renal transplantation.
C) Sevoflurane is safe in patients with ESRD because it undergoes no hepatic metabolism whatsoever and generates neither inorganic fluoride nor compound A; the renal concerns associated with sevoflurane apply only to patients with normal renal function in whom fluoride-mediated concentrating defects can be clinically detected by urine osmolality testing — a test that is irrelevant in anuric patients.
D) Sevoflurane is clinically appropriate for patients with ESRD: inorganic fluoride from sevoflurane metabolism may accumulate at higher serum levels in patients with reduced renal clearance, but clinical nephrotoxicity from sevoflurane has not been demonstrated even in patients with impaired renal function, and compound A's nephrotoxicity in humans has not been established; sevoflurane is widely used in ESRD patients with appropriate fresh gas flow precautions and is not contraindicated on the basis of either metabolite pathway.
E) Sevoflurane is contraindicated in patients with ESRD because hexafluoroisopropanol (HFIP) — sevoflurane's primary co-metabolite — is a potent vasoconstrictor of the renal microvasculature that, in patients with pre-existing renovascular disease from diabetic nephropathy or hypertension, causes permanent obliteration of residual renal arterioles and prevents any future kidney transplant from achieving adequate perfusion.

ANSWER: D

Rationale:

Evaluating sevoflurane safety in a patient with ESRD requires accurate knowledge of both metabolite pathways and the clinical evidence regarding their actual nephrotoxic risk. Sevoflurane undergoes approximately 3 to 5% hepatic CYP2E1 metabolism, generating inorganic fluoride ions and hexafluoroisopropanol (HFIP). Inorganic fluoride is normally renally cleared, and in a patient with ESRD, reduced clearance could theoretically lead to higher serum fluoride levels. However, the concern about fluoride nephrotoxicity was derived from methoxyflurane, which caused nephrotoxicity through extensive intrarenal metabolism generating fluoride locally within tubular cells. Sevoflurane's intrarenal metabolism is limited, and the serum fluoride levels generated do not produce the same local tubular concentration that drove methoxyflurane nephrotoxicity. Multiple clinical studies in patients with renal impairment have not demonstrated clinical nephrotoxicity attributable to sevoflurane. For compound A — the CO₂ absorbent degradation product — nephrotoxicity in rats has been demonstrated, but human clinical studies at standard low-flow use have not confirmed clinically significant renal dysfunction. In an ESRD patient whose renal function is already absent and who is dependent on dialysis, the theoretical concern about aggravating renal function is moot — there is no residual renal function to preserve or damage. Sevoflurane is used routinely in ESRD patients on dialysis and is not contraindicated on the basis of either metabolite pathway, provided standard precautions (adequate fresh gas flows of at least 2 L/min to limit compound A generation) are observed. Option A: Fluoride retention in anuric patients from sevoflurane metabolism has not been shown to produce fluoride intoxication syndrome with cardiac arrhythmias, bone demineralization, or CNS toxicity. The serum fluoride levels generated from sevoflurane are substantially lower than those from methoxyflurane, and clinical fluoride toxicity from sevoflurane has not been demonstrated in ESRD patients. The claim that fluoride is not effectively dialyzed is also inaccurate — fluoride is dialyzable. This option overstates the risk dramatically, making it incorrect. Option B: Compound A is a volatile organic molecule that does not accumulate in the circulation of anuric patients in the manner described. It is generated in the breathing circuit and is inhaled as a gas; it does not undergo renal excretion as its primary elimination pathway. The claim that it reaches nephrotoxic concentrations within 30 minutes and causes irreversible tubular necrosis preventing transplant success describes a clinical toxicity that has not been established in humans at standard use, making this option incorrect. Option C: Sevoflurane does undergo hepatic metabolism — approximately 3 to 5% — and does generate inorganic fluoride. Stating that it undergoes no metabolism is factually incorrect. Additionally, compound A is generated by CO₂ absorbent interaction regardless of the patient's renal function status, making this option incorrect. Option D: Correct. Sevoflurane is clinically appropriate in ESRD patients — fluoride accumulation may occur but has not been shown to cause toxicity, compound A nephrotoxicity has not been established in humans, and in an anuric dialysis-dependent patient the theoretical renal concerns are further mitigated by the absence of functioning renal tissue to protect; standard fresh gas flow precautions are appropriate. Option E: Hexafluoroisopropanol (HFIP) is not a vasoconstrictor of the renal microvasculature, and there is no established mechanism by which HFIP obliterates residual renal arterioles or prevents future transplant perfusion. This describes a non-existent pharmacological mechanism, making this option incorrect.

11. A 58-year-old man with a history of alcohol use disorder and known nutritional deficiency is admitted to the ICU following multi-organ failure after emergency bowel resection. He has been difficult to sedate adequately with standard IV agents alone, and the ICU team proposes adding inhaled nitrous oxide (N₂O) at 50% inspired concentration via a specialized delivery system for 72 hours to supplement sedation. The intensivist asks whether there are specific toxicity concerns with prolonged nitrous oxide exposure in ICU patients, and whether this patient has any feature that increases his risk. Which of the following correctly identifies the primary toxicity concern, its mechanism, and the patient factor that amplifies risk?

A) The primary toxicity concern with 72-hour nitrous oxide sedation is progressive bowel gas expansion producing tension pneumoperitoneum; the patient's recent bowel resection leaves residual air-filled loops that will expand over 72 hours of nitrous oxide exposure, and the anastomotic suture lines are at particular risk of disruption from the rising intraluminal pressure.
B) The primary toxicity concern is nitrous oxide-induced sympathomimetic cardiovascular stimulation producing sustained tachycardia and hypertension over 72 hours; in a patient with multi-organ failure, this sustained catecholamine-like state will accelerate myocardial oxygen consumption and precipitate demand ischemia, and alcohol use disorder amplifies the risk through baseline cardiomyopathy.
C) The primary toxicity concern is progressive diffusional hypoxia developing over the 72-hour exposure period as nitrous oxide equilibrates throughout body fat compartments; alcohol use disorder amplifies the risk because ethanol-induced adipose redistribution increases the fat compartment volume available for nitrous oxide accumulation, prolonging the diffusional hypoxia phase when the agent is discontinued.
D) The primary toxicity concern is anesthetic tolerance developing over 72 hours of nitrous oxide exposure through upregulation of NMDA (N-methyl-D-aspartate) receptors, which produces cross-tolerance to standard IV sedatives and increases their dosing requirements by 3 to 4 fold after nitrous oxide discontinuation; alcohol use disorder amplifies the risk through pre-existing NMDA receptor upregulation from chronic alcohol withdrawal.
E) The primary toxicity concern is irreversible inactivation of vitamin B₁₂ by nitrous oxide through oxidation of the cobalt ion, leading to methionine synthase inhibition, impaired DNA synthesis in rapidly proliferating cells, and risk of megaloblastic bone marrow failure and subacute combined degeneration of the spinal cord with prolonged exposure; this patient's alcohol use disorder is associated with pre-existing nutritional vitamin B₁₂ deficiency, which substantially reduces his reserve and makes even moderate-duration exposure potentially sufficient to precipitate these complications.

ANSWER: E

Rationale:

Prolonged nitrous oxide administration in an ICU setting carries a specific and serious toxicity risk that is entirely distinct from its acute intraoperative concerns: irreversible inactivation of vitamin B₁₂. Nitrous oxide oxidizes the cobalt ion at the center of the vitamin B₁₂ molecule from its active reduced form to an inactive oxidized form, inactivating methionine synthase — the enzyme required for conversion of homocysteine to methionine and for regeneration of tetrahydrofolate needed for thymidylate synthesis. This impairs DNA synthesis in rapidly dividing cells, with clinically significant consequences most prominent in hematopoietic precursors (megaloblastic bone marrow failure, megaloblastic anemia) and neurological tissue (subacute combined degeneration of the spinal cord — a demyelinating myelopathy affecting posterior and lateral columns). The duration and concentration of nitrous oxide exposure govern the risk: a single brief anesthetic infrequently causes clinical manifestations, but prolonged exposure (as in repeated ICU sedation or prolonged dressing changes) produces cumulative irreversible inactivation. This patient's alcohol use disorder is directly relevant: chronic alcohol excess is strongly associated with nutritional vitamin B₁₂ deficiency through inadequate dietary intake, impaired gastric acid production reducing intrinsic factor availability, and direct effects on ileal B₁₂ absorption. A patient with pre-existing B₁₂ deficiency has a dramatically reduced reserve: even a moderate-duration exposure to nitrous oxide sufficient to inactivate residual methionine synthase may precipitate clinically significant megaloblastic crisis or accelerate neuropathy. Seventy-two hours of 50% nitrous oxide in a B₁₂-deficient patient represents a serious and avoidable risk that should preclude this approach unless no alternatives exist and B₁₂ status is confirmed and supplemented. Option A: Bowel gas expansion is a legitimate acute concern with nitrous oxide in patients with bowel obstruction or free intraperitoneal gas. However, following bowel resection with anastomosis, the surgical bowel is not an air-filled sealed space in the same way as an obstructed loop — the abdomen is closed and the bowel is decompressed at surgery. More critically, the 72-hour prolonged sedation context makes the B₁₂ toxicity the primary and specific concern for this patient's individual risk factor profile. Bowel anastomotic disruption from nitrous oxide in a post-resection patient is a theoretical concern but not the primary toxicity of prolonged nitrous oxide in this scenario, making this option incorrect. Option B: Nitrous oxide's sympathomimetic cardiovascular effect is mild — it tends to maintain rather than markedly elevate heart rate and blood pressure through modest central sympathetic stimulation. Describing it as producing a sustained catecholamine-like state over 72 hours causing demand ischemia overstates its hemodynamic magnitude substantially. Alcohol use disorder is associated with cardiomyopathy, but the cardiovascular mechanism described is not the primary or specific concern for prolonged nitrous oxide in this patient, making this option incorrect. Option C: Diffusional hypoxia is a transient phenomenon occurring at emergence when nitrous oxide rapidly exits the alveolus. It does not develop progressively over 72 hours of exposure and does not relate to body fat compartment volume. The mechanism described is pharmacologically inaccurate for prolonged administration, making this option incorrect. Option D: NMDA receptor upregulation producing cross-tolerance to IV sedatives is not a recognized clinical consequence of 72-hour nitrous oxide exposure. While NMDA receptor mechanisms are relevant to both nitrous oxide action and alcohol dependence, the described cross-tolerance phenomenon with a 3 to 4 fold increase in sedative dosing requirements is not pharmacologically established, making this option incorrect. Option E: Correct. Prolonged nitrous oxide exposure irreversibly inactivates vitamin B₁₂, inhibiting methionine synthase and impairing DNA synthesis, with risk of megaloblastic bone marrow failure and subacute combined degeneration; this patient's alcohol use disorder-associated B₁₂ deficiency dramatically reduces his reserve and amplifies the risk of clinically significant toxicity from 72-hour exposure.